14 research outputs found

    The Agentcities Network Architecture

    Get PDF
    Agentcities is a worldwide initiative designed to help realize the commercial and research potential of agent-based applications by constructing an open distributed network of platforms hosting diverse agents and services. The ultimate aim of the Agentcities initiative is to enable the dynamic, intelligent and autonomous composition of services to achieve user and business goals, thereby creating compound services to address changing needs. In this paper, we present the progress and current status of the Agentcities Network, six months after the launch of the project. The architecture of the Network, consisting of agents, services and platforms, is described. Finally, the plans and challenges for enhancing the Agentcities Network in the next phase of development are also discussed

    Characterization of the interaction of multivalent glycosylated ligands with bacterial lectins by biolayer interferometry

    No full text
    International audienceThe study of multivalent carbohydrate–protein interactions remains highly complicated and sometimes rendered impossible due to aggregation problems. Biolayer interferometry is emerging as a tool to monitor such complex interactions. In this study, various glycoclusters and dendrimers were prepared and evaluated as ligands for lectins produced by pathogenic bacteria Pseudomonas aeruginosa (LecA and Lec B) and Burkholderia ambifaria (BambL). Reliable kinetic and thermodynamic parameters could be measured, and immobilization of either lectin or ligands resulted in high quality data. The methods gave results in full agreement with previous isothermal titration calorimetry experiments, and presented strong advantages because they require less quantity and purity for the biomolecules

    Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

    No full text

    Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

    No full text
    10.1161/CIRCULATIONAHA.119.042551CIRCULATION140191578-158

    Alirocumab reduces total hospitalizations and increases days alive and out of hospital in the ODYSSEY OUTCOMES trial

    No full text

    Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    No full text
    corecore